Search
Norelgestromin
go.drugbank.com/drugs/DB06713ApprovedInvestigationalNorelgestromin was first approved in the United States in 2001 as the progestin in a norelgestromin and ethinyl estradiol transdermal contraceptive system.[L63816] … [L63816] Combined hormonal contraceptives containing norelgestromin lower the risk of pregnancy primarily by suppressing ovulation.
Mixtures: Norelgestromin and Ethinly Estradiol, Norelgestromin and Ethinyl EstradiolCategories: norelgestromin and ethinylestradiol, Genito Urinary System and Sex HormonesAlbiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnIt is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. … Albiglutide was approved on April 15, 2014 by the FDA.
Categories: Alimentary Tract and Metabolism, Hormones, Hormone Substitutes, and Hormone AntagonistsNaloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalIt was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. … The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system
Categories: Alimentary Tract and MetabolismR673
go.drugbank.com/drugs/DB05466ExperimentalThe phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning … of limbic system with respect to anxiety and depression.
Difelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigational[A237610] These revelations led to the study of KOR agonists as a potential treatment option in patients suffering from pruritic conditions. … [L36420,L36395] Difelikefalin was later approved by the EMA in April 2022 for the same indication.[L41665]
Caroxazone
go.drugbank.com/drugs/DB09254ApprovedWithdrawnCaroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes.
Batroxobin
go.drugbank.com/drugs/DB09005InvestigationalThe MW of batroxobin is approximately 43,000 g/mol-1, and it contains 231 amino acids. Batroxobin is inactivated by alpha2-macroglobulin, but not anti-thrombin compounds. … Currently use is experimental but trials have been conducted which support certain clinical applications. Recombinant Batroxobin in relatively affordable and could be accessed by mass production.
Categories: Enzymes and Coenzymes, Blood and Blood Forming OrgansVerteporfin
go.drugbank.com/drugs/DB00460ApprovedInvestigationalVerteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet … oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.
MK-0736
go.drugbank.com/drugs/DB15209InvestigationalMK-0736 is under investigation in clinical trial NCT00679055 (A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)).
Modafinil
go.drugbank.com/drugs/DB00745ApprovedInvestigationalNarcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. … The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular
Categories: Modafinil and isomer, Metabolic Side Effects of Drugs and Substances